ENANTA PHARMACEUTICALS, INC Increase (Decrease) in Income Taxes Receivable
ENANTA PHARMACEUTICALS, INC (ENTA) reported Increase (Decrease) in Income Taxes Receivable of $0 for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes receivable for the quarter ending 2026-06-30 was -$19.00K.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes receivable for the quarter ending 2026-03-31 was $19.00K, a 98.64% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes receivable for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes receivable for the quarter ending 2025-09-30 was -$24.00K.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes receivable for fiscal 2025 was -$32.00M, a 3315.98% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes receivable for fiscal 2024 was $995.00K, a 56.47% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes receivable for fiscal 2023 was $2.29M.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes receivable for fiscal 2022 was -$8.54M, a 135.26% decline from fiscal 2021.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | -$24.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $19.00K 10-Q · filed 2026-05-13 | -$5.00K derived: sum of 3 quarters · filed 2026-05-13 | -$33.82M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 10-Q · filed 2026-02-11 | -$24.00K derived: sum of 2 quarters · filed 2026-02-11 | -$33.84M derived: sum of 3 quarters · filed 2026-08-12 | -$32.44M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | -$33.84M derived: sum of 2 quarters · filed 2026-08-12 | -$32.44M derived: sum of 3 quarters · filed 2026-08-12 | -$32.00M 10-K · filed 2025-11-19 |
| 2025-06-30 | -$33.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | -$32.42M derived: sum of 2 quarters · filed 2026-08-12 | -$31.98M 10-Q · filed 2026-08-12 | -$32.43M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $1.84M 10-Q · filed 2026-05-13 | $1.38M derived: sum of 3 quarters · filed 2026-05-13 | $1.80M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $445.00K 10-Q · filed 2026-02-11 | -$11.00K derived: sum of 2 quarters · filed 2026-02-11 | $413.00K derived: sum of 3 quarters · filed 2026-02-11 | $710.00K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | -$456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | -$32.00K derived: sum of 2 quarters · filed 2025-11-19 | $265.00K derived: sum of 3 quarters · filed 2025-11-19 | $995.00K 10-K · filed 2025-11-19 |
| 2024-06-30 | $424.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-13 | $721.00K derived: sum of 2 quarters · filed 2025-08-13 | $1.45M 10-Q · filed 2025-08-13 | $6.54M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-03-31 | $297.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $1.03M 10-Q · filed 2025-05-14 | $6.11M derived: sum of 3 quarters · filed 2025-11-19 | $3.26M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-12-31 | $730.00K 10-Q · filed 2025-02-12 | $5.82M derived: sum of 2 quarters · filed 2025-11-19 | $2.96M derived: sum of 3 quarters · filed 2025-11-19 | $3.03M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-09-30 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $2.23M derived: sum of 2 quarters · filed 2025-11-19 | $2.30M derived: sum of 3 quarters · filed 2025-11-19 | $2.29M 10-K · filed 2025-11-19 |
| 2023-06-30 | -$2.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-07 | -$2.79M derived: sum of 2 quarters · filed 2024-08-07 | -$2.80M 10-Q · filed 2024-08-07 | -$2.81M derived: sum of 4 quarters · filed 2024-11-27 |
| 2023-03-31 | $71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08 | $56.00K 10-Q · filed 2024-05-08 | $46.00K derived: sum of 3 quarters · filed 2024-11-27 | $26.00K derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-12-31 | -$15.00K 10-Q · filed 2024-02-08 | -$25.00K derived: sum of 2 quarters · filed 2024-11-27 | -$45.00K derived: sum of 3 quarters · filed 2024-11-27 | -$48.00K derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-09-30 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27 | -$30.00K derived: sum of 2 quarters · filed 2024-11-27 | -$33.00K derived: sum of 3 quarters · filed 2024-11-27 | -$8.54M 10-K · filed 2024-11-27 |
| 2022-06-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | -$23.00K derived: sum of 2 quarters · filed 2023-08-08 | -$8.53M 10-Q · filed 2023-08-08 | -$1.84M derived: sum of 4 quarters · filed 2023-11-22 |
| 2022-03-31 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-09 | -$8.51M 10-Q · filed 2023-05-09 | -$1.82M derived: sum of 3 quarters · filed 2023-11-22 | $15.71M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-12-31 | -$8.50M 10-Q · filed 2023-02-08 | -$1.82M derived: sum of 2 quarters · filed 2023-11-22 | $15.71M derived: sum of 3 quarters · filed 2023-11-22 | $18.90M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-09-30 | $6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-22 | $24.21M derived: sum of 2 quarters · filed 2023-11-22 | $27.40M derived: sum of 3 quarters · filed 2023-11-22 | $24.21M 10-K · filed 2023-11-22 |
| 2021-06-30 | $17.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | $20.72M derived: sum of 2 quarters · filed 2022-08-08 | $17.53M 10-Q · filed 2022-08-08 | $17.39M derived: sum of 4 quarters · filed 2022-11-23 |
| 2021-03-31 | $3.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-09 | $0.00 10-Q · filed 2022-05-09 | -$141.00K derived: sum of 3 quarters · filed 2022-11-23 | |
| 2020-12-31 | -$3.19M 10-Q · filed 2022-02-10 | -$3.33M derived: sum of 2 quarters · filed 2022-11-23 | ||
| 2020-09-30 | -$141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23 | $4.13M 10-K · filed 2022-11-23 | ||
| 2020-06-30 | $4.27M 10-Q · filed 2021-08-09 | |||
| 2019-09-30 | $8.92M 10-K · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |